Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356408 | 0.85 | ACACB (0.58) | ACACBLDHASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14370510 | 0.85 | ACACB (0.58) | ACACBLDHASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14534148 | 0.84 | ACACB (0.57) | ACACBLDHASMN1; SMN2 | |
| SCHEMBL5481870 | 0.84 | ACACB (0.57) | ACACBLDHASMN1; SMN2ALDH1A1FPR2 | |
| SCHEMBL4358254 | 0.84 | ACACB (0.57) | ACACBLDHASMN1; SMN2ALDH1A1FPR2 | |
| SCHEMBL14534150 | 0.84 | ACACB (0.68) | ACACBLDHASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL13953675 | 0.82 | ACACB (0.55) | ACACBLDHA | |
| SCHEMBL21496803 | 0.81 | ACACB (0.54) | ACACBLDHASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL21496808 | 0.81 | ACACB (0.54) | ACACBLDHASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL19569846 | 0.80 | ACACB (0.53) | ACACBLDHASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619116-B2 | Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | Products Chimiques Auxiliaires Et de Synthese (FR) | 2009-11-17 | — | — | US | disclosed |
| EP-1697316-B1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF (R)-TAMSULOSIN AND OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THEIR PREPARATION | PROD CHIM AUXILIAIRES ET DE SY (FR) | 2008-10-08 | — | — | EP | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | ACACB 3915/4885LDHA 3340/4885SMN1; SMN2 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.